Branch	Locations	Status	Reservations	Due date	Barcode	Floor plan	Lending note
Branch: Hauptstelle	Locations: ZB-90 213	Status: available	Reservations: 0	Due date:	Barcode: 00182290	Floor plans: Floor plan	Lending note:

About this book

 

This is the first book to cover every angle in the clinical application of biologics.

 

Prepared and edited by two leading clinicians in the field, including the prize-winning dermatologist Wolf-Henning Boehncke, this work carries complete authority.

 

Readers will find that all of the biologics currently approved for clinical use are delineated in a standardized way, including crucial information that is of practical use in the field, such as contra-indications or monitoring needs.

 

They will also find covered the whole area of "differential therapy" with biologics in fields such as dermatology, neurology, rheumatology and gastroenterology. This differential therapy is described in detail and summarized in treatment algorithms.

 

While these more clinically oriented chapters form the core of this essential text, the editors have taken care to ensure that other issues are covered too. Thus, included are shorter sections on biologic biotechnology, as well as the safety, regulatory, and pharmaco-economic issues surrounding biologics.

 

 

Table of contents

 

Definition and classification of biologics.- Development and pre-clinical pharmacology of biologics: Infliximab from the idea to the product. Adalimumab. Etanercept. Efalizumab (Raptiva) antibody characteristics, mode of action and preclinical development. Monoclonal antibody targeted radiation cancer therapy. The production of biopharmaceuticals.- Disease-specific applications and clinical trials: Treating autoimmune bullous skin disorders with biologics. Biologics in psoriasis. Biologic agents in psoriatic arthritis. Biologic therapies for rheumatoid arthritis targeting TNFa and IL-1. Biologics in Crohns Disease and ulcerative colitis. Multiple sclerosis: new immunobiologics. Biologics in cutaneous lymphoma. Biologics in targeted cancer therapy.- Safety and Perspectives: Safety aspects of biologics lessons learnt from monoclonal antibodies. New biological therapeutics in the genome age. Evidence-based medicines perspective on biologics.